Influence of proteasome inhibitors on apoptosis.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Proteasome inhibitors are a novel class of drugs that alter normal cellular control of apoptosis. As such, they are being investigated as novel therapies to alter uncontrolled cellular proliferation and treat cancers. This review explores new information about how the proteasome regulates apoptosis and how proteasome inhibitors can be exploited as anti-tumor drugs. RECENT FINDINGS: Proteasome inhibitors block the activation of nuclear factor kappa B in a number of cell systems, as well as altering apoptotic regulatory proteins and intracellular signals that influence the fate of the cell. These effects are true for many tumor cell lines. The US Food and Drug Administration-approved proteasome inhibitor bortezomib blocks erroneous cell proliferation and induces apoptosis in many tumor models. SUMMARY: Proteasome inhibitors have demonstrated promise in vitro, and as a result clinical trials have begun to investigate these agents as therapy for numerous human cancers. Furthermore, newer agents are being designed to inhibit the proteasome system and exert further anti-tumor activity.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalCurrent opinion in clinical nutrition and metabolic care.
Volume9
Issue number1
StatePublished - Jan 2006

Fingerprint

Proteasome Inhibitors
proteasome endopeptidase complex
apoptosis
Apoptosis
neoplasms
Proteasome Endopeptidase Complex
Neoplasms
Cell Proliferation
cell proliferation
NF-kappa B
United States Food and Drug Administration
Tumor Cell Line
Pharmaceutical Preparations
drugs
therapeutics
regulatory proteins
Cell Count
Clinical Trials
clinical trials
Therapeutics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Influence of proteasome inhibitors on apoptosis. / Rizza, Stacey; Badley, Andrew David.

In: Current opinion in clinical nutrition and metabolic care., Vol. 9, No. 1, 01.2006, p. 42-47.

Research output: Contribution to journalArticle

@article{14b54ec849324393ab58021946329ac1,
title = "Influence of proteasome inhibitors on apoptosis.",
abstract = "PURPOSE OF REVIEW: Proteasome inhibitors are a novel class of drugs that alter normal cellular control of apoptosis. As such, they are being investigated as novel therapies to alter uncontrolled cellular proliferation and treat cancers. This review explores new information about how the proteasome regulates apoptosis and how proteasome inhibitors can be exploited as anti-tumor drugs. RECENT FINDINGS: Proteasome inhibitors block the activation of nuclear factor kappa B in a number of cell systems, as well as altering apoptotic regulatory proteins and intracellular signals that influence the fate of the cell. These effects are true for many tumor cell lines. The US Food and Drug Administration-approved proteasome inhibitor bortezomib blocks erroneous cell proliferation and induces apoptosis in many tumor models. SUMMARY: Proteasome inhibitors have demonstrated promise in vitro, and as a result clinical trials have begun to investigate these agents as therapy for numerous human cancers. Furthermore, newer agents are being designed to inhibit the proteasome system and exert further anti-tumor activity.",
author = "Stacey Rizza and Badley, {Andrew David}",
year = "2006",
month = "1",
language = "English (US)",
volume = "9",
pages = "42--47",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Influence of proteasome inhibitors on apoptosis.

AU - Rizza, Stacey

AU - Badley, Andrew David

PY - 2006/1

Y1 - 2006/1

N2 - PURPOSE OF REVIEW: Proteasome inhibitors are a novel class of drugs that alter normal cellular control of apoptosis. As such, they are being investigated as novel therapies to alter uncontrolled cellular proliferation and treat cancers. This review explores new information about how the proteasome regulates apoptosis and how proteasome inhibitors can be exploited as anti-tumor drugs. RECENT FINDINGS: Proteasome inhibitors block the activation of nuclear factor kappa B in a number of cell systems, as well as altering apoptotic regulatory proteins and intracellular signals that influence the fate of the cell. These effects are true for many tumor cell lines. The US Food and Drug Administration-approved proteasome inhibitor bortezomib blocks erroneous cell proliferation and induces apoptosis in many tumor models. SUMMARY: Proteasome inhibitors have demonstrated promise in vitro, and as a result clinical trials have begun to investigate these agents as therapy for numerous human cancers. Furthermore, newer agents are being designed to inhibit the proteasome system and exert further anti-tumor activity.

AB - PURPOSE OF REVIEW: Proteasome inhibitors are a novel class of drugs that alter normal cellular control of apoptosis. As such, they are being investigated as novel therapies to alter uncontrolled cellular proliferation and treat cancers. This review explores new information about how the proteasome regulates apoptosis and how proteasome inhibitors can be exploited as anti-tumor drugs. RECENT FINDINGS: Proteasome inhibitors block the activation of nuclear factor kappa B in a number of cell systems, as well as altering apoptotic regulatory proteins and intracellular signals that influence the fate of the cell. These effects are true for many tumor cell lines. The US Food and Drug Administration-approved proteasome inhibitor bortezomib blocks erroneous cell proliferation and induces apoptosis in many tumor models. SUMMARY: Proteasome inhibitors have demonstrated promise in vitro, and as a result clinical trials have begun to investigate these agents as therapy for numerous human cancers. Furthermore, newer agents are being designed to inhibit the proteasome system and exert further anti-tumor activity.

UR - http://www.scopus.com/inward/record.url?scp=33646243806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646243806&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 42

EP - 47

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 1

ER -